Back to search

Virginia Commonwealth University

THE SECOND GENERATION PROTEASOME INHIBITOR CARFILZOMIB INTERACTS SYNERGISTICALLY WITH HDAC INHIBITORS IN DIFFUSE LARGE B-CELL LYMPHOMA CELLS THROUGH MULTIPLE MECHANISMS AND CIRCUMVENTS BORTEZOMIB RESISTANCE

Abstract

dc:description.abstract

Mechanisms underlying the interactions between the proteasome inhibitor carfilzomib and HDAC inhibitors were examined in both germinal center (GC) and activated B-cell (ABC) subtypes of human diffuse large B-cell lymphoma (DLBCL). Simultaneous exposure to minimally toxic concentrations of carfilzomib and HDAC inhibitor vorinostat resulted in the release of mitochondrial pro-apoptotic proteins SMAC and cytochrome c, pro-apoptotic caspase activation, and synergistic induction in apoptosis in both ABC and GC DLBCL subtypes. These events were associated with a marked increase in the stress kinase JNK, ROS generation, G2-M cell cycle arrest, as well as induction of DNA damage. Genetic knockdown of JNK resulted in a significant decrease in carfilzomib/vorinostat induced cell death. Co-administration of the antioxidant MnTBAP significantly reduced carfilzomib/vorinostat induced cell death, and resulted in a marked decrease in caspase-3 as well as a striking decrease in JNK phosphorylation. Tumor growth reduction was also observed in animal models that were treated with a combined regimen of carfilzomib and vorinostat. Finally, the combined treatment of carfilzomib/vorinostat was able to overcome any cross-resistance to carfIlzomib in bortezomib resistant cells. Collectively, these finding indicate that the combined regimen of carfilzomib and HDAC inhibitors promote lethality in ABC and GC human DLBCL cells by a variety of mechanisms both in vitro and in vivo. Further studies are necessary for clinical development of this drug regimen.

Degree

thesis:*
Name thesis:degree_name
Master of Science
Level thesis:degree_level
Thesis
Discipline thesis:degree_discipline
Biochemistry

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Lembersky, Dmitry
Contributors dc:contributor
  • Steven Grant

Subjects

dc:subject × 3

Rights

dc:rights
Statement dc:rights
  • © The Author

Identifiers

dc:identifier.*

Chain of custody

source
Harvested from
Virginia Commonwealth University
Base URL
scholarscompass.vcu.edu/do/oai/
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
citation

Lembersky, Dmitry. THE SECOND GENERATION PROTEASOME INHIBITOR CARFILZOMIB INTERACTS SYNERGISTICALLY WITH HDAC INHIBITORS IN DIFFUSE LARGE B-CELL LYMPHOMA CELLS THROUGH MULTIPLE MECHANISMS AND CIRCUMVENTS BORTEZOMIB RESISTANCE. Thesis thesis, https://doi.org/10.25772/WSKN-JT96